Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ventus Therapeutics

News headline image
Ventus Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of VENT-03, a Novel Small Molecule cGAS Inhibitor, in Patients with Lupus
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics Enters into a Collaboration and License Agreement with Genentech to Discover and Develop Small-Molecule Medicines Using Ventus' ReSOLVE® Platform
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics to Present Phase 1 Results for VENT-03, a First-in-Class cGAS Inhibitor, at LUPUS 2025
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics Announces Publication in Nature’s Communications Chemistry Describing the Structure-based Optimization of a New Series of cGAS Inhibitors
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating VENT-02, an Oral, Brain-Penetrant NLRP3 Inhibitor, in Parkinson’s Disease
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics Announces Nature Reviews Immunology Publication Demonstrating the Promise of Caspase-4/5 as Therapeutic Targets
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics Appoints Mona Kotecha, M.D., as Chief Medical Officer
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics Significantly Expands its Presence in Montreal, Canada with Opening of a New Laboratory and Office Facility
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics to Present at the Stifel 2023 Healthcare Conference
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics Named a “Fierce 15” Biotech Company of 2023
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics Initiates Dosing in a Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics to Present at the Canadian Chemistry Conference and Exhibition
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics Hosts Inaugural Program Spotlight: VENT-03, a First-in-Class cGAS Inhibitor
From Ventus Therapeutics
Via Business Wire
News headline image
Ventus Therapeutics Awarded Grant by The Michael J. Fox Foundation to Support Development of a NLRP3 PET Tracer
From Ventus Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.